For the first time, scientists have managed to restore central vision loss from an irreversible age-related eye condition via ...
Why scale matters when the disease is slow but relentless Dry age-related macular degeneration progresses in quiet increments ...
Second-generation anti-VEGF agents, like aflibercept 8 mg and faricimab, show improved efficacy and treatment durability in ...
A whisper-thin chip, smart glasses and patient training are reshaping how older people live with central vision loss across ...
DMT to receive $85 million upfront cash payment and expect to receive at least $50 million of cost sharing from Otsuka over the next three years for development activities supporting global ...
A tiny chip, smart glasses and months of training are rewriting what blindness means for older people with failing central ...
Around a third of people over the age of 80 suffer from age-related macular degeneration (AMD), with an estimated 20 million ...
Everest Medicines acquired an exclusive license to develop, manufacture, and commercialize VIS-101 in Greater China, Singapore, South Korea, and certain ...
NovaBridge subsidiary Visara assigned its exclusive license to Everest Medicines to accelerate the development of potential best-in-class therapy for wet AMD, VIS-101, leveraging Everest Medicines' ...
Generated $459 million in 3Q 2025 revenues, including $178 million in U.S. net product salesReceived 152 new patient start forms for EMPAVELI® ...
UCSF scientists reveal how the KLF15 protein converts white fat into brown fat that burns energy, offering new hope for ...
Windy City Retina - Age-related Macular Degeneration (AMD), diabetic retinopathy, and retinal detachment are three leading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback